PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BEAM vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BEAM and CRSP is 0.68, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.7

Performance

BEAM vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Beam Therapeutics Inc. (BEAM) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%80.00%AugustSeptemberOctoberNovemberDecember2025
25.01%
-25.40%
BEAM
CRSP

Key characteristics

Sharpe Ratio

BEAM:

-0.04

CRSP:

-0.67

Sortino Ratio

BEAM:

0.52

CRSP:

-0.83

Omega Ratio

BEAM:

1.06

CRSP:

0.91

Calmar Ratio

BEAM:

-0.03

CRSP:

-0.41

Martin Ratio

BEAM:

-0.07

CRSP:

-0.86

Ulcer Index

BEAM:

40.04%

CRSP:

38.85%

Daily Std Dev

BEAM:

72.94%

CRSP:

49.94%

Max Drawdown

BEAM:

-86.76%

CRSP:

-81.74%

Current Drawdown

BEAM:

-82.46%

CRSP:

-80.70%

Fundamentals

Market Cap

BEAM:

$1.94B

CRSP:

$3.46B

EPS

BEAM:

-$1.58

CRSP:

-$2.80

Total Revenue (TTM)

BEAM:

$33.45M

CRSP:

$1.62M

Gross Profit (TTM)

BEAM:

$16.97M

CRSP:

-$118.31M

EBITDA (TTM)

BEAM:

-$299.05M

CRSP:

-$387.56M

Returns By Period

In the year-to-date period, BEAM achieves a -5.48% return, which is significantly lower than CRSP's 2.97% return.


BEAM

YTD

-5.48%

1M

-12.70%

6M

-9.64%

1Y

-1.06%

5Y*

N/A

10Y*

N/A

CRSP

YTD

2.97%

1M

0.36%

6M

-25.71%

1Y

-34.62%

5Y*

-7.04%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BEAM vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BEAM
The Risk-Adjusted Performance Rank of BEAM is 4444
Overall Rank
The Sharpe Ratio Rank of BEAM is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of BEAM is 4646
Sortino Ratio Rank
The Omega Ratio Rank of BEAM is 4444
Omega Ratio Rank
The Calmar Ratio Rank of BEAM is 4343
Calmar Ratio Rank
The Martin Ratio Rank of BEAM is 4444
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 1818
Overall Rank
The Sharpe Ratio Rank of CRSP is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1313
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 1616
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2121
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BEAM vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BEAM, currently valued at -0.04, compared to the broader market-2.000.002.004.00-0.04-0.67
The chart of Sortino ratio for BEAM, currently valued at 0.52, compared to the broader market-4.00-2.000.002.004.000.52-0.83
The chart of Omega ratio for BEAM, currently valued at 1.06, compared to the broader market0.501.001.502.001.060.91
The chart of Calmar ratio for BEAM, currently valued at -0.03, compared to the broader market0.002.004.006.00-0.03-0.41
The chart of Martin ratio for BEAM, currently valued at -0.07, compared to the broader market-10.000.0010.0020.00-0.07-0.86
BEAM
CRSP

The current BEAM Sharpe Ratio is -0.04, which is higher than the CRSP Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of BEAM and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.40AugustSeptemberOctoberNovemberDecember2025
-0.04
-0.67
BEAM
CRSP

Dividends

BEAM vs. CRSP - Dividend Comparison

Neither BEAM nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BEAM vs. CRSP - Drawdown Comparison

The maximum BEAM drawdown since its inception was -86.76%, which is greater than CRSP's maximum drawdown of -81.74%. Use the drawdown chart below to compare losses from any high point for BEAM and CRSP. For additional features, visit the drawdowns tool.


-84.00%-82.00%-80.00%-78.00%-76.00%-74.00%-72.00%AugustSeptemberOctoberNovemberDecember2025
-82.46%
-80.70%
BEAM
CRSP

Volatility

BEAM vs. CRSP - Volatility Comparison

Beam Therapeutics Inc. (BEAM) has a higher volatility of 18.32% compared to CRISPR Therapeutics AG (CRSP) at 13.43%. This indicates that BEAM's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
18.32%
13.43%
BEAM
CRSP

Financials

BEAM vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Beam Therapeutics Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab